Clinical Trial Update: Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituximab and Fludarabine followed by alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Campath-1H (alemtuzumab)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non-Hodgkins Lymphoma | Phase 2 | Status: COMPLETED